Institutional members access full text with Ovid®

Share this article on:

First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: a case report

Baraboutis, Ioannis G.a; Papastamopoulos, Vassiliosa; Charitsis, Georgiosb; Lekakis, Lazaros J.c; Vaslamatzis, Michael M.c; Skoutelis, Athanasios T.a b

European Journal of Gastroenterology & Hepatology: May 2008 - Volume 20 - Issue 5 - p 472-473
doi: 10.1097/MEG.0b013e3282f16411
Case Reports

We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.

aInfectious Diseases and AIDS Division

b5th Department of Internal Medicine

c‘Evaggelismos’, General Hospital, Athens, Greece

Correspondence to Dr Ioannis G. Baraboutis, MD, Infectious Diseases and AIDS Division, ‘Evaggelismos’ General Hospital, 45–47 Ipsilantou Street, Athens 10676, Greece

Tel: +30 210 7201242; fax: +30 210 7201320;

e-mail: ioannisbaraboutis@yahoo.gr

Received 11 April 2007 Accepted 9 July 2007

© 2008 Lippincott Williams & Wilkins, Inc.